334 related articles for article (PubMed ID: 36171533)
21. Efficacy and Safety of Transarterial Chemoembolization Plus Donafenib with or without Immune Checkpoint Inhibitors as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Deng L; Sun Y; Wang H; Liao C; Li D; Xu G; Yang X
J Hepatocell Carcinoma; 2024; 11():29-38. PubMed ID: 38223554
[TBL] [Abstract][Full Text] [Related]
22. Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study.
Zhang CS; Zeng ZM; Zhuo MY; Luo JR; Zhuang XH; Xu JN; Zeng J; Ma J; Lin HF
Oncologist; 2023 Dec; 28(12):e1239-e1247. PubMed ID: 37329569
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Wen W; Zhang Y; Zhang H; Chen Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):969-978. PubMed ID: 35771261
[TBL] [Abstract][Full Text] [Related]
25. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis.
Xian F; Wu C; Zhang G; Xu G
Medicine (Baltimore); 2022 Nov; 101(44):e31479. PubMed ID: 36343054
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Wang S; Wang Y; Yu J; Wu H; Zhou Y
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428618
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
Fulgenzi CAM; D'Alessio A; Airoldi C; Scotti L; Demirtas CO; Gennari A; Cortellini A; Pinato DJ
Eur J Cancer; 2022 Oct; 174():57-67. PubMed ID: 35970037
[TBL] [Abstract][Full Text] [Related]
30. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
31. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
Celsa C; Cabibbo G; Pinato DJ; Di Maria G; Enea M; Vaccaro M; Battaglia S; Rizzo GEM; Giuffrida P; Giacchetto CM; Rancatore G; Grassini MV; Cammà C
Liver Cancer; 2024 Apr; 13(2):169-180. PubMed ID: 38751554
[TBL] [Abstract][Full Text] [Related]
32. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
Liu K; Zhu Y; Zhu H
Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
[TBL] [Abstract][Full Text] [Related]
34. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.
Kudo M; Finn RS; Galle PR; Zhu AX; Ducreux M; Cheng AL; Ikeda M; Tsuchiya K; Aoki KI; Jia J; Lencioni R
Liver Cancer; 2023 Aug; 12(3):238-250. PubMed ID: 37767068
[TBL] [Abstract][Full Text] [Related]
35. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.
Tian JC; Liu H; Yan LJ; Ding ZN; Han CL; Tian BW; Tan SY; Dong ZR; Wang DX; Xue JS; Mao XC; Yan YC; Li T
Clin Exp Med; 2023 Oct; 23(6):2115-2129. PubMed ID: 36385419
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
Chen K; Wei W; Liu L; Deng ZJ; Li L; Liang XM; Guo PP; Qi LN; Zhang ZM; Gong WF; Huang S; Yuan WP; Ma L; Xiang BD; Li LQ; Zhong JH
Cancer Immunol Immunother; 2022 May; 71(5):1063-1074. PubMed ID: 34559308
[TBL] [Abstract][Full Text] [Related]
38. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials.
Fulgenzi CAM; Scheiner B; Korolewicz J; Stikas CV; Gennari A; Vincenzi B; Openshaw MR; Silletta M; Pinter M; Cortellini A; Scotti L; D'Alessio A; Pinato DJ
JHEP Rep; 2023 May; 5(5):100702. PubMed ID: 37025943
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Liu J; Yang L; Wei S; Li J; Yi P
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16191-16201. PubMed ID: 37658861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
